DRugwatch BlogRSS 2.0

DRugwatch Blog > January 2012

  • 1/20/2012 2:12:09 PM
    A New Era and Market Opportunity for Multaq
    Matt Kileen 1/19/2012 6:15:13 PM
    Paula Deen and Questioning Celebrity Drug Endorsements
    Contributor: Allison Thrower

    If time and tradition are any indicators, celebrity pharmaceutical endorsements will be an advertising trend for years to come...
  • 1/17/2012 4:47:06 PM
    The current shortage of Doxil across the major markets
    Matt Kileen 1/9/2012 8:04:20 PM
    Diabetes Drug Development: 2011 Year in Review and a Look Ahead Towards 2012 And Beyond – Part 2
    Matt Kileen 1/6/2012 5:25:06 PM
    Diabetes Drug Development: 2011 Year in Review and a Look Ahead Towards 2012 And Beyond – Part 1
    Matt Kileen


    rss twitter linkedin


    DRugwatch Blog

    Quick insight on intriguing drug market developments from Decision Resources’ analysts.

    Recent posts

    Post title:
    The Budgetary Impact of Diabetic Comorbidities in Brazil and Mexico - How Little is Being Done to Measure and Control It
    Post date:
    8/31/2015 10:48:39 AM
    Post Summary:
    The type 2 diabetes (T2D) therapy market is often tied to a high commercial opportunity. Indeed, when we look at key Latin American markets such as Brazil and Mexico -- each with over 14 million prevalent cases of T2D and growing, and Mexico with one of the highest prevalence rates in the world -- it is unsurprising that Brazil’s and Mexico’s total pharmaceutical market for type 2 diabetes rival the size of some of the more mature markets.

    Post title:
    2015 ESC Congress in London – Overview of Upcoming Hot Line Sessions
    Post date:
    7/2/2015 11:57:46 PM
    Post Summary:
    Conor WalshContributor: Conor Walsh M.Sc., Ph.D.
    Topics: Conference Commentary, Cardiovascular

    This year’s ESC congress will take place in the Excel Exhibition Centre in London, United Kingdom. The spotlight this year is “environment and the heart,” highlighting the many different kinds of interactions between the environment and cardiovascular diseases.

    Post title:
    FDA Approval for The Medicines Company’s Intravenous Antiplatelet Kengreal
    Post date:
    6/23/2015 1:22:54 PM
    Post Summary:
    Conor WalshContributors: Conor Walsh, M.Sc., Ph.D.
    Topics: Cardiovascular

    On June 22nd, 2015 the U.S. FDA approved Kengreal (cangrelor), the Medicines Company’s intravenous antiplatelet drug for use “as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction, repeat coronary revascularization, and stent thrombosis in patients in who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.”

    Post title:
    Hematological Malignancies: Are Immune Checkpoint Inhibitors Checking-in?
    Post date:
    6/17/2015 9:32:42 AM
    Post Summary:
    Contributor: Dana Gheorghe, Ph.D
    : Conference Commentary, Oncology

    Recent years have seen an added emphasis on the relationship between cancer and the activity of the immune system. Novel agents that aim to harness the immune system have already been approved in the U.S. for solid tumors (Bristol-Myers Squibb/Ono Pharmaceutical’s Opdivo [nivolumab] for NSCLC and malignant melanoma, and Merck & Co.’s Keytruda [pembrolizumab] for malignant melanoma), and are in development for a plethora of other oncology indications. Most of the development has been targeted towards solid tumors, but the potential of immune checkpoint inhibitors in hematological malignancies is becoming increasingly evident.

    Post title:
    Cardiovascular Outcomes Trials Answer Long-Asked Questions – But New Questions Arise
    Post date:
    6/12/2015 10:26:05 AM
    Post Summary:
    Contributor: Eamonn O'Connor, Ph.D.

    The recent American Diabetes Association’s 75th Scientific Sessions in Boston saw the release of data from the ELIXA cardiovascular outcomes trial (CVOT) for lixisenatide (Sanofi/Zealand Pharma’s Lyxumia), the first such trial completed for the GLP-1 receptor agonist drug class. However, it was the publication of the data from the CVOT for sitagliptin (Merck’s Januvia/Ono’s Glactiv), known as TECOS1, that was most eagerly anticipated; this is because the previous CVOTs for saxagliptin (AstraZeneca’s Onglyza) and alogliptin (Takeda/Furiex’s Nesina/Vipidia) had raised significant concerns about a potential risk for increased rates of hospitalization due to heart failure. The results from TECOS therefore, were viewed as pivotal as to whether this risk was a feature specific to the DPP-IV inhibitor drug class.

    Decision Resources Group brands include: